Among all the NCCN_NSCLC targets, 30% were PD‐L1 positive (TPS ≥ 1%; 6/20), followed by TMB‐H (20%, 4/20) and METex14 (15%, 3/20). Here, CD274 is linked to non-small cell lung carcinoma.